Highlights

  • Cynata Therapeutics has reported top-line results from the University of Sydney's Phase 3 SCUlpTOR trial of CYP-004 in patients with knee osteoarthritis, with no statistically significant differences between active and control groups on either co-primary endpoint.
  • CYP shares fell sharply on the news, trading at AUD 0.019, down 92.69%, or AUD 0.24, as at 10:37 am on 19 June 2026.
  • Following the CYP-004 results and the previously announced Phase 2 CYP-001 trial outcomes, the company is now actively reviewing options for further development of its Cymerus technology platform.

Cynata Therapeutics Limited (ASX:CYP), listed on the Australian Securities Exchange under the ticker CYP, announced on 19 June 2026 that it has received top-line results from the University of Sydney's Phase 3 SCUlpTOR trial evaluating CYP-004 in patients with osteoarthritis of the knee. The trial found no statistically significant differences between the active and control groups on either of the co-primary endpoints. The proportion of participants reaching the patient-acceptable symptom state threshold for knee pain at 24 months was 51.7% in the active group compared with 48.1% in the control group, a difference that did not reach statistical significance.

On the second co-primary endpoint, relating to cartilage thickness, the active group recorded a mean loss of central medial femorotibial cartilage thickness of 0.27mm compared with 0.21mm in the control group, also not statistically significant. The company reported no safety concerns from the trial, noting a similar adverse event profile between the two groups.

Share Price Reaction

CYP shares were recorded at AUD 0.019 at 10:37 am on 19 June 2026, reflecting a decline of 92.69%, or AUD 0.24, for the session. The scale of the movement reflects the market's reaction to a clinical trial outcome that fell short of the efficacy benchmarks the company had been targeting, particularly given the unexpectedly higher-than-anticipated response rate observed in the placebo control group. For a clinical-stage biotechnology company, news of this nature, where a late-stage trial does not demonstrate clear separation from placebo on its primary endpoints, typically carries material weight for near-term share price performance.

Secondary Endpoint Showed Pain Reduction, But No Group Separation

As a secondary endpoint, the trial measured knee pain intensity from 3 to 24 months relative to baseline. Both groups recorded a reduction in pain scores over this period, with an average reduction of 26.8 out of 100 in the active group and 25.3 out of 100 in the control group after 24 months. However, the company stated there were no significant differences between the two groups at any timepoint measured, meaning the pain reduction observed could not be specifically attributed to the CYP-004 treatment relative to placebo. Cynata noted that analysis of additional outcome measures from the trial is ongoing and will be reported in due course.

Trial Design and Conduct

CYP-004 is Cynata's Cymerus off-the-shelf, induced pluripotent stem cell-derived mesenchymal stem cell product candidate, designed for intra-articular injection. The SCUlpTOR trial was a randomised, placebo-controlled Phase 3 study conducted by the University of Sydney, with funding provided under an Australian Government National Health and Medical Research Council project grant. Patients in the trial were randomised to receive intra-articular injections of either saline, as the placebo control, or CYP-004, as the active treatment. The trial was led by Professor David Hunter, the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney and Royal North Shore Hospital.

Management Response

Dr Kilian Kelly, Cynata's CEO and Managing Director, described the results as disappointing, noting that the pain reduction observed in the control group was considerably better than the study design had anticipated. The trial's design had assumed that 35% of control patients would reach the patient-acceptable symptom state threshold, whereas the actual figure was closer to 50%. Dr Kelly said the pain reduction in the active group was in line with company expectations, but added that there was no evidence of a reduction in cartilage loss in that group. He thanked Professor Hunter, the study team, and the patients who participated in the trial.

Cymerus Platform Under Strategic Review

The CYP-004 results follow closely on the previously announced outcomes of the Phase 2 trial of CYP-001 in patients with acute graft versus host disease, disclosed in an announcement dated 17 June 2026. In light of the combined outcomes from both trials, Cynata stated that it is now actively reviewing options for further development of its Cymerus technology platform, with the company indicating it will provide an update on this review as soon as possible. This sequence of two trial readouts in close succession represents a significant juncture for the company's clinical pipeline strategy.

Upcoming Investor Webinar

Cynata announced that an investor webinar will be held on Monday 22 June 2026 at 8:30am AEST, hosted by CEO and Managing Director Dr Kilian Kelly together with Chair Dr Geoff Brooke. The company has provided a registration link for shareholders and other interested parties wishing to attend and hear further detail on the trial results and the company's strategic review.

Company Background

Cynata Therapeutics describes itself as an Australian clinical-stage stem cell and regenerative medicine company focused on therapies based on Cymerus, its proprietary therapeutic stem cell platform technology. The company states that Cymerus is designed to overcome challenges associated with conventional mesenchymal stem cell production by using induced pluripotent stem cells, enabling economic manufacture of cell therapy products at commercial scale without ongoing reliance on tissue from multiple donors, and without the complexity and product inconsistency associated with conventional production methods.

In summary, the Phase 3 SCUlpTOR trial of CYP-004 did not demonstrate statistically significant separation from placebo on either of its co-primary endpoints relating to symptom relief or cartilage preservation, despite an acceptable safety profile across both treatment groups. Combined with the recent Phase 2 CYP-001 trial outcomes, this result has prompted Cynata to undertake a broader review of the future direction of its Cymerus platform, with further detail expected to be provided to the market following the company's investor webinar scheduled for 22 June 2026.